First domino, named next dominoes: management generalizes a fresh win into a repeatable template and points to the speci
The model's full reasoning — Q3 2016 call → NOWe need answer only YES or NO. Need analyze transcript. Need determine if management takes recent real success and generalizes as repeatable template, identifies specific next places already in motion. Let's parse. Company Fate Therapeutics. Programs: ProTmune clinical trial, FATE-NK100 IND filed, ToleraCyte pre-IND, iPSC platform, partnership with MSK. Need see if any "recent real success" achieved and generalized as template with specific next applications. Possible candidates: - ProTmune: clinical trial protocol amended, enrollment open at seven sites. Not a success? No product launched. No. - FATE-NK100: IND filed, preclinical data. Not yet clinical. No. - ToleraCyte: pre-IND meeting positive. No. - iPSC platform: engineered pluripotent cell lines. They have partnership with MSK. They plan to submit briefing package to FDA. No proven first instance? Maybe they have "successfully shown" engineered iPSC derived NK cells have improved persistence etc. But that's preclinical, not a real business success. No. - Partnership with Memorial Sloan-Kettering: multiyear partnership aimed at T cell immunotherapy. Is that a recent real success? They formed partnership and exclusively licensed IP. But is it a "won customer, completed project, successful product introduction, first site, market, program, or partnership that is now demonstrably working and producing real business"? It's a partnership, but not producing real business yet. They are combining teams. Not demonstrably working. No. Need see if management explicitly generalizes a success as template and identifies next places. Maybe in context of FATE-NK100: "While conventional NK cell therapies have shown promise... FATE-NK100 is enriched..." They have IND filed, plan to initiate in AML. They might say "we will aggressively look to advance FATE-NK100 in two different settings of both solid and liquid tumors" but not specific next places? In Q&A, Scott says "we will aggressively look to advance FATE-NK100 in two different settings of both solid and liquid tumors and we do not necessarily believe that the results in AML read on those particular settings." That's not specific next places, just broad. Maybe ProTmune: They amended protocol to broaden label by including MDS and CML, CMV negative. That's expanding eligibility, not template.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| MCD | McDonald's Corporation | Q2 2024 | 2024-07-29 | D |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| LOW | Lowe's Companies, Inc. | Q3 2021 | 2021-11-17 | B+ |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| ACHC | Acadia Healthcare Company, Inc. | Q4 2017 | 2018-02-22 | C+ |
T · Q3 2018 → YESThe question is: Does management take a RECENT, REAL SUCCESS and explicitly GENERALIZE it as a template they can repeat, AND identify SPECIFIC NEXT PLACES where that template is already being applied?...YES The transcript shows management treating the AdWorks success (22% revenue growth on a declining subscriber base) as a proven template for targeted advertising, then explicitly identifying the next applications: applying the same technology to Turner inventory and signing up additional distributors (Frontier and Altice) as concrete next repetitions already in motion. 5G and FirstNet do not qualify because their first instances are still prospective or ongoing without a completed, repeatable proof-of-concept.
LOW · Q3 2021 → YESThe question is about whether management takes a recent real success and generalizes it as a template they're applying to specific next places. YES The transcript shows management treating the market-based delivery model as a proven template after the first success in Florida and the second in Ohio Valley this quarter. They explicitly generalize it as a repeatable approach that is already driving measurable results (higher sales in appliances, improved margins, reduced inventory, higher on-time delivery) and plan 18+ months of rollout across the entire US.
FLR · Q2 2022 → YESThe question is about whether management takes a recent, real success and generalizes it as a template they can repeat, and identifies specific next places where it's being applied. YES The transcript shows management treating the LNG 1 project (awarded last quarter) as a proven template: David Constable states they have “proven that our mid-scale modular design and execution plans facilitates repeatable models that can be used to replicate and fast track similar LNG plants in the future.